Adalimumab

The U.S. Department of Veterans Affairs will replace Humira with the biosimilar Hadlima on its national formulary, according to a press release from Organon, which markets biosimilar.

CVS Caremark, one of the nation’s largest pharmacy benefit managers, will remove Humira from its major national commercial formularies effective April 1 in favor of biosimilar options, according to a press release from the company.

Patients reported low overall satisfaction with New Zealand’s mandatory nationwide transition to an adalimumab biosimilar, though most said they are still taking it and appreciated its less-painful injections, according to a study.

News pertaining to biosimilars came at a fast and furious pace in 2023.

Among patients with rheumatoid arthritis, the chosen course of therapy does not have an impact on the risk for developing a serious infection, according to data published in Rheumatology.

A combination of vedolizumab, adalimumab and methotrexate resulted in endoscopic remission at week 26 in more than a third of patients with Crohn’s disease, according to data in Clinical Gastroenterology and Hepatology.

The FDA has approved Abrilada as the second interchangeable biosimilar to adalimumab, according to a press release from Pfizer.

The FDA has granted de novo clearance to ProciseDx Inc. for its therapeutic drug monitoring tests for Humira and Remicade, as well as their biosimilars, in patients with inflammatory bowel disease, according to a company release.

Although the current net price of adalimumab biosimilar Amjevita is lower for commercial health plans than that of the originator, it is nonetheless “more than double” what Humira cost at launch in 2003, according to a research letter.

The adalimumab biosimilar Hadlima achieved its pharmacokinetic similarity endpoints in a phase 4 interchangeability study, according to a press release from the manufacturer.